一分钟看懂
这是一项关于Hypertrophic Cardiomyopathy (HCM)的不适用研究，登记的药物或干预包括diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids；Close follow-up；early rehabilitation guidance，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids；Close follow-up；early rehabilitation guidance · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Renji Hospital · 上海
公开的入选条件
- * Age 18-75 years old.
- * Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.
- * No history of structural heart disease, and the Framingham score \<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography/coronary CT/exercise platelet).
- * Creatinine clearance ≥50ml/min (Cockcroft-Gault formula).
- * LVEF ≥50% assessed by Echocardiography.
- * QT interval \< 470 ms.
- * Providing written informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06794710；登记信息更新于 2025-01-27。